Upregulated EGFR activity is a major drug target for the treatment of solid tumours and the microtubule-dependent transport of EGFR endosomal vesicles by α-tubulin acetylation links HDAC6 to the pathogenesis of prostate, pancreatic, and lung cancer cells [13]. This evidence concerns the gene HDAC6 and lung carcinoma.